{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:44:49Z","timestamp":1762821889749,"version":"build-2065373602"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.retram.2023.103424","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:21:48Z","timestamp":1697772108000},"page":"103424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic\/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-4176","authenticated-orcid":false,"given":"Matthieu","family":"Decamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4983-5581","authenticated-orcid":false,"given":"Emilie","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Godon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Lestringant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Roynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Jimenez-Pocquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Roche-Lestienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2023.103424_bib0003","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"6020","key":"10.1016\/j.retram.2023.103424_bib0004","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"issue":"4944","key":"10.1016\/j.retram.2023.103424_bib0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210 bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.retram.2023.103424_bib0006","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103424_bib0007","article-title":"CML\u2014Where do we stand in 2015?","volume":"94 Suppl 2:S103-5","author":"Hehlmann","year":"2015","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.retram.2023.103424_bib0008","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.retram.2023.103424_bib0009","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0010","first-page":"35","article-title":"Complex chromosome rearrangements may locate the bcr\/abl fusion gene sites other than 22q11","volume":"85","author":"Sessarego","year":"2000","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.retram.2023.103424_bib0011","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0012","first-page":"628","article-title":"The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia","volume":"9","author":"Anastasi","year":"1995","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0013","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-4608(85)90041-X","article-title":"Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression","volume":"18","author":"Swolin","year":"1985","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cancergencyto.2010.02.003","article-title":"Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications","volume":"199","author":"Zaccaria","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0016","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0017","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood-2007-05-092437","article-title":"Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia","volume":"110","author":"De Melo","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0018","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0019","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cancergen.2012.09.003","article-title":"The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate","volume":"205","author":"Lee","year":"2012","journal-title":"Cancer Genet"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0020","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.retram.2023.103424_bib0021","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00277-013-1816-z","article-title":"Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy","volume":"92","author":"Wang","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.retram.2023.103424_bib0022","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2018.208801","article-title":"Poor prognosis of chromosome 7 clonal aberrations in philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia","volume":"104","author":"Bidet","year":"2019","journal-title":"Haematologica"},{"issue":"5531","key":"10.1016\/j.retram.2023.103424_bib0023","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bulcan.2019.05.011","article-title":"Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia","volume":"107","author":"Cayuela","year":"2020","journal-title":"Bull Cancer"},{"issue":"22","key":"10.1016\/j.retram.2023.103424_bib0025","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMc035089","article-title":"A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia","volume":"348","author":"Roche-Lestienne","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.retram.2023.103424_bib0026","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"Roche-Lestienne","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0027","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0028","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0029","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0030","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.leukres.2010.07.012","article-title":"Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients","volume":"35","author":"Joha","year":"2011","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0031","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-07-102533","article-title":"RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL + leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance","volume":"111","author":"Roche-Lestienne","year":"2008","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.retram.2023.103424_bib0032","first-page":"6588","article-title":"Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p","volume":"52","author":"Yandell","year":"1992","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0033","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2217\/fon.15.64","article-title":"3q26\/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review","volume":"11","author":"de Braekeleer","year":"2015","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.retram.2023.103424_bib0034","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41375-018-0136-7","article-title":"Validation of the EUTOS long-term survival score in a recent independent cohort of \u201creal world\u201d CML patients","volume":"32","author":"Geelen","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0035","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa writing committee for the collaborative CML prognostic factors project group","volume":"90","author":"Hasford","year":"1998","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0036","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0037","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0038","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.3390\/jcm9113671","article-title":"The new eln recommendations for treating cml","volume":"9","author":"Hehlmann","year":"2020","journal-title":"J Clin Med"},{"issue":"26","key":"10.1016\/j.retram.2023.103424_bib0039","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0040","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0041","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cancergencyto.2006.12.011","article-title":"Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case","volume":"176","author":"Zeidan","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0042","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","article-title":"Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"108","author":"Kovitz","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0043","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","article-title":"Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase","volume":"140","author":"Lauseker","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0044","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/10428190410001723278","article-title":"Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib","volume":"45","author":"Loriaux","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071712","article-title":"The cytogenetic landscape of pediatric chronic myeloid leukemia diagnosed in chronic phase","volume":"14","author":"Karow","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.retram.2023.103424_bib0046","first-page":"511","article-title":"Cytogenetics in the management of \u201cchronic myeloid leukemia\u201d: an update by the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","volume":"74","author":"Roche-Lestienne","year":"2016","journal-title":"Ann Biol Clin"},{"issue":"9","key":"10.1016\/j.retram.2023.103424_bib0047","doi-asserted-by":"crossref","first-page":"e27827","DOI":"10.1002\/pbc.27827","article-title":"Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children's Oncology Group CML Working Group","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.retram.2023.103424_bib0048","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2017.165795","article-title":"Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera","volume":"102","author":"Tang","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0049","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/genes13040637","article-title":"Genetic background of polycythemia vera","volume":"13","author":"Regimbeau","year":"2022","journal-title":"Genes (basel)"},{"issue":"21","key":"10.1016\/j.retram.2023.103424_bib0051","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2020010402","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms","volume":"138","author":"Marcault","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2023.103424_bib0052","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0053","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.14798","article-title":"Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance","volume":"182","author":"Barraco","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.retram.2023.103424_bib0054","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.retram.2023.103424_bib0056","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0057","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-022-00639-z","article-title":"Cytogenetic abnormalities in essential thrombocythemia: clinical and molecular correlates and prognostic relevance in 809 informative cases","volume":"12","author":"Gangat","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0058","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0059","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.13260","article-title":"A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients","volume":"169","author":"Wassie","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cells12010105","article-title":"Impact of molecular biology in diagnosis, prognosis, and therapeutic management of BCR::ABL1-negative myeloproliferative neoplasm","volume":"12","author":"Abbou","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0061","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0062","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0063","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0064","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","article-title":"WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature","volume":"19","author":"Elliott","year":"2005","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.retram.2023.103424_bib0065","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0066","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.retram.2023.103424_bib0067","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25906","article-title":"A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States","volume":"95","author":"Ruan","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.retram.2023.103424_bib0068","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0069","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25811","article-title":"WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL,NOS): a contemporary series from the Mayo Clinic","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.retram.2023.103424_bib0070","article-title":"A novel IL3-ETV6 fusion in chronic eosinophilic leukemia not otherwise specified with t(5; 12) (q31; p13): a case report and literature review","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0071","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0072","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.retram.2023.103424_bib0073","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2021004237","article-title":"A novel activating JAK1 mutation in chronic eosinophilic leukemia","volume":"5","author":"Shomali","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0074","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000518737","article-title":"Chronic eosinophilic leukaemia associated with JAK2 Exon 13 insertion\/deletion mutations","volume":"145","author":"Lafferty","year":"2022","journal-title":"Acta Haematol"},{"issue":"26","key":"10.1016\/j.retram.2023.103424_bib0075","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1182\/blood.2019001385","article-title":"JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.retram.2023.103424_bib0076","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European working group on myelodysplastic syndromes in childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0077","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/ped.13068","article-title":"Diagnosis and treatment of juvenile myelomonocytic leukemia","volume":"58","author":"Sakashita","year":"2016","journal-title":"Pediatr Int"},{"issue":"10","key":"10.1016\/j.retram.2023.103424_bib0078","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who\u2019s the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0079","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12185-014-1715-7","article-title":"Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan","volume":"101","author":"Yabe","year":"2015","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00431-019-03468-8","article-title":"PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center","volume":"179","author":"Miao","year":"2020","journal-title":"Eur J Pediatr"},{"issue":"17","key":"10.1016\/j.retram.2023.103424_bib0081","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103424_bib0082","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2023.103424_bib0083","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2009.016345","article-title":"Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis","volume":"95","author":"Erben","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0084","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.14748","article-title":"Molecular monitoring of patients with ETV6-PDGFRB rearrangement: implications for therapeutic adaptation","volume":"182","author":"Bidet","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.retram.2023.103424_bib0085","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0086","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study","volume":"32","author":"Tang","year":"2019","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.retram.2023.103424_bib0087","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","article-title":"Myeloid\/lymphoid neoplasms with FLT3 rearrangement","volume":"34","author":"Tang","year":"2021","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.retram.2023.103424_bib0088","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.retram.2023.103424_bib0089","first-page":"614","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia\/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition","volume":"106","author":"Yao","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0090","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0091","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","article-title":"Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","volume":"29","author":"Verstovsek","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.retram.2023.103424_bib0092","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosom Cancer"},{"issue":"12","key":"10.1016\/j.retram.2023.103424_bib0093","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/ajh.25265","article-title":"Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases","volume":"93","author":"Shah","year":"2018","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.retram.2023.103424_bib0094","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2023.103424_bib0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004\u201315","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0096","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0097","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.retram.2023.103424_bib0098","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.retram.2023.103424_bib0099","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.retram.2023.103424_bib0100","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.retram.2023.103424_bib0101","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.3390\/ijms21186862","article-title":"Atypical chronic myeloid leukemia: where are we now?","volume":"21","author":"Cris\u00e0","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0102","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.retram.2023.103424_bib0103","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1002\/ajh.26182","article-title":"Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)","volume":"96","author":"Montalban-Bravo","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0104","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3324\/haematol.2009.013631","article-title":"Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis","volume":"95","author":"Flach","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.retram.2023.103424_bib0105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.retram.2023.103424_bib0106","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/hematology.2020000130","article-title":"Genomics of myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"20","author":"Patnaik","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.retram.2023.103424_bib0107","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103424_bib0108","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2023.103424_bib0109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1016\/j.retram.2023.103424_bib0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.retram.2023.103424_bib0111","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891961","article-title":"Chronic neutrophilic leukemia: a comprehensive review of clinical characteristics, genetic landscape and management","volume":"12","author":"Thomopoulos","year":"2022","journal-title":"Front Oncol."},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0112","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3390\/medicina57111135","article-title":"Precision medicine in systemic mastocytosis","volume":"57","author":"Nicolosi","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.retram.2023.103424_bib0113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.756348","article-title":"Molecular pathogenesis of BCR-ABL-negative atypical chronic myeloid leukemia","volume":"11","author":"Fontana","year":"2021","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.retram.2023.103424_bib0114","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.retram.2023.103424_bib0115","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2023.103424_bib0116","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127127","article-title":"High-risk additional chromosomal abnormalities in CML herald death by blast crisis already at low blast levels","volume":"134","author":"Hehlmann","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2023.103424_bib0117","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862300048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862300048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:42:13Z","timestamp":1762821733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245231862300048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S245231862300048X"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2023.103424","relation":{},"ISSN":["2452-3186"],"issn-type":[{"type":"print","value":"2452-3186"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic\/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2023.103424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103424"}}